Molecular Insights into the Specific Targeting of c-MYC G-Quadruplex by Thiazole Peptides

Sen Cao1, Qian Su1, Yong-Hao Chen2

  • 1Institute of Ageing Research, School of Basic Medical Sciences, Hangzhou Normal University, Hangzhou 311121, China.

Insights

A novel thiazole peptide, TH3, selectively binds to the c-MYC G-quadruplex (G4) by forming a unique stacking framework. This discovery advances cancer treatment strategies by guiding the development of more targeted G4 stabilizers.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Computational Chemistry

Background:

  • G-quadruplex (G4) stabilization in the c-MYC proto-oncogene promoter inhibits gene expression, offering a cancer therapy strategy.
  • Existing G4 stabilizers lack selectivity, targeting multiple G4 structures in DNA and RNA.
  • The thiazole peptide TH3 shows preferential stabilization of the c-MYC G4, but the binding mechanism is unclear.

Purpose of the Study:

  • To elucidate the atomic-level mechanisms behind the selective binding of TH3 to the c-MYC G4.
  • To compare the binding of TH3 and its analogue TH1 to G4s from c-MYC, c-KIT1, c-KIT2, and BCL2 promoters.

Main Methods:

  • In silico comparative investigation using molecular docking and molecular dynamics simulations.
  • Analysis of non-covalent interactions and binding free energies (bulk and per-nucleotide).

Main Results:

  • Both TH3 and TH1 form a sandwich-like framework with the c-MYC G4 and capping nucleotides, enhancing binding affinity.
  • TH3 demonstrates superior binding priority to the c-MYC G4 compared to other promoter G4s.
  • Van der Waals interactions are identified as the primary force in complex formation for all studied G4s.

Conclusions:

  • The study reveals the specific binding mechanisms of TH3 to the c-MYC G4, involving a unique stacking framework.
  • These findings support experimental data and provide a basis for designing novel, selective G4 stabilizers for cancer therapy.